Kan ik het krijgen?
Ja, als een arts bepaalt dat het geschikt voor u is. Saxenda is goedgekeurd in de EU en kan na een medische beoordeling worden voorgeschreven.
SaxendaAlleen op recept
Online medisch consult voor Saxenda.
Een door de EU erkende arts beoordeelt uw casus en, indien in aanmerking komend, geeft een elektronisch recept af dat geldig is bij elke EU-apotheek onder Richtlijn 2011/24/EU.
- Daily pen with flexible titration
- One of the longest-standing GLP-1s in Europe
- An option when a weekly GLP-1 isn't the right fit
Start consultStart consult · € 25/maand
Volledige terugbetaling als een beoordeling niet wordt goedgekeurd · Medicatie wordt, indien voorgeschreven, apart verstrekt en betaald bij een apotheek.
IN GEWONE TAAL
Wat Saxenda is en hoe u een behandeling krijgt
Liraglutide is een medicijn dat eenmaal per dag onder de huid wordt geïnjecteerd. Net als semaglutide bootst het het natuurlijke darmhormoon GLP-1 na. Dit hormoon laat de hersenen weten dat u genoeg hebt gegeten, waardoor honger en trek in eten afnemen. Voor gewichtsbeheersing wordt het in de EU als Saxenda verkocht en samen met een caloriearmere voeding en meer lichaamsbeweging gebruikt. Het is in de EU sinds maart 2015 goedgekeurd voor gewichtsbeheersing.
Saxenda is sinds 23 maart 2015 toegelaten voor gebruik in de EU. Een bevoegde arts kan het daarom voorschrijven wanneer het medisch geschikt voor u is.
Lees meer over peptiden op Peptidepedia.
Wat kan ik in plaats daarvan nemen?
Onze artsen beoordelen alle opties voor Gewichtsbeheersing en adviseren wat past bij uw medische voorgeschiedenis en doelen.
Bekijk alle opties voor GewichtsbeheersingWat laten de studies zien?
Alle studies naar Saxenda staan hieronder met hun registratienummer, het aantal deelnemers en de vermelding of de resultaten door andere wetenschappers zijn beoordeeld of alleen door het bedrijf zijn aangekondigd.
Ga naar de studiesGEVERIFIEERD BEWIJS
Saxenda: gids voor bewijs en regelgeving.
WAT HET IS
Hoe het werkt
It copies the gut hormone GLP-1, which increases the feeling of fullness and reduces hunger and food cravings.
- GLP-1
ONTWIKKELINGSFASE
EU-goedgekeurd geneesmiddel
Studieregister1 geregistreerde studies
Elke NCT-code linkt naar ClinicalTrials.gov. Een gemelde uitkomst is niet hetzelfde als een peer-reviewed publicatie.
| STUDIE / NCT | POPULATIE | DEELNEMERS | STATUS | RESULTAAT / VOLTOOIING |
|---|---|---|---|---|
| SCALE Obesity and Prediabetes (NN8022-1839)NCT01272219 | Adults with a BMI of 30 kg/m² or more, or 27 kg/m² or more with treated high blood pressure or abnormal blood fats, without type 2 diabetes; all received lifestyle counselling | 3,731 | Uitgelezen | 2015-07-02 |
Wat de studies meldden
Resultaten zijn gescheiden op bron en bewijskracht, zodat tijdschriftgegevens niet met fabrikantaankondigingen worden verward.
Peer-reviewed
Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. doi:10.1056/NEJMoa1411892 (PMID 26132939)| DOSIS OF GROEP | GEMIDDELDE GEWICHTSVERANDERING | WEKEN |
|---|---|---|
| 3.0 mg once daily | −8.0% | 56 |
| Placebo | −2.6% | 56 |
Everyone in the trial also received lifestyle counselling, people with type 2 diabetes were excluded, and the primary result covers 56 weeks only.
BENOEMDE VEILIGHEIDSSIGNALEN
Wat bij Saxenda is gemeld.
Nausea
Reported by 40.2% of people on liraglutide 3.0 mg versus 14.7% on placebo in the SCALE Obesity and Prediabetes trial.
Diarrhoea
Reported by 20.9% on liraglutide 3.0 mg versus 9.3% on placebo in the same trial.
Constipation
Reported by 20.0% on liraglutide 3.0 mg versus 8.7% on placebo in the same trial.
Vomiting
Reported by 16.3% on liraglutide 3.0 mg versus 4.1% on placebo in the same trial.
Gallstone problems
Acute gallstone events were reported by 2.3% on liraglutide 3.0 mg versus 0.9% on placebo across the EMA weight-management trial pool, mainly gallstones (1.5% versus 0.5%).
Acute pancreatitis
Independently confirmed in 7 people (0.2%) on liraglutide 3.0 mg versus 1 person (under 0.1%) on placebo across the EMA weight-management trial pool.
Serious side effects overall
Serious adverse events were reported in 6.2% of the liraglutide group versus 5.0% of the placebo group in the SCALE Obesity and Prediabetes trial.
€ 25/maand (gefactureerd € 25 per 28 dagen)Start een medisch consult
VormVoorgevulde injectiepen
FrequentieEenmaal daags
ResultatenGradual, week by week
Wat je Hi-Doctor betaalt€ 25/maand (gefactureerd € 25 per 28 dagen)
IN 60 SECONDEN
Saxenda in het kort
- A GLP-1 receptor agonist given as an injection under the skin once a day.
- Adults with a BMI of 30 or more, or 27 or more plus a weight-related illness.
- One injection every day, at any time, built up from 0.6 mg to 3.0 mg.
- Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
MERKGEGEVENS
Saxenda in het kort
- HANDELSVERGUNNINGHOUDER
- Novo Nordisk A/S
- TOEDIENINGSVORMEN
- 6 mg/ml solution for injection in a pre-filled pen
Over de behandeling
Wat is Saxenda?
Saxenda bevat de werkzame stof liraglutide.
Werkzame stof: Liraglutide · Doseringen: 0.6 – 3 mg / day
Liraglutide is a GLP-1 receptor agonist given as a daily subcutaneous injection. It was one of the first in its class approved in Europe for weight management in adults with obesity, or overweight with comorbidities.
Compared with weekly GLP-1s, its daily dosing can be useful when flexibility of adjustment matters or when a semaglutide hasn't been tolerated. The doctor weighs this up in your consultation — two GLP-1 agonists are never combined.
HOE HET WERKT
Wat Saxenda in je lichaam doet
Like other GLP-1 analogues, liraglutide mimics a natural gut hormone: it eases hunger signals and produces earlier fullness, so you tend to eat less. Being shorter-acting, its dose is adjusted day by day.
Copies one gut hormone
Liraglutide is a copy of a natural gut hormone called GLP-1, which the body releases after eating. The EU product information describes it as an acylated human GLP-1 analogue with 97% amino acid sequence homology to the human hormone, and it binds to and activates the GLP-1 receptor.
Raises fullness, lowers hunger
GLP-1 receptors also sit in brain regions that regulate appetite. The product information reports that liraglutide increases feelings of fullness and satiety while lowering hunger and prospective food consumption, so people eat less. It does not increase energy expenditure compared with placebo.
Short-acting, so taken daily
Liraglutide has an elimination half-life of roughly 13 hours, which is why it is injected once every day rather than once a week like semaglutide or tirzepatide. It also raises insulin and lowers glucagon in a glucose-dependent way, and weight is lost mainly as fat mass.
Hoe het helpt
Three ways it supports weight loss.
Eases appetite
Earlier fullness and calmer hunger signals through the day.
Flexible dosing
Daily titration lets the doctor fine-tune the dose to your tolerance.
Long EU history
Among the first weight-management GLP-1s approved in Europe.
Wat u kunt verwachten
A gradual, week-by-week build-up.
Treatment starts at a low daily dose and steps up through the intermediate doses as tolerated. Your doctor sets the pace and adjusts if side effects appear.
- Week 1 · 0.6 mg daily starting dose
- Following weeks · Step up through 1.2, 1.8 and 2.4 mg as tolerated
- Maintenance · 3 mg daily when appropriate
- Ongoing · Follow-up through your account chat
Typical escalation
- Starting dose0.6 mg / day
- Step-ups1.2 → 1.8 → 2.4 mg / day
- Maintenance3 mg / day
Uw schema is persoonlijk
Deze stappen zijn slechts richtlijnen. Uw arts past het plan aan op hoe u reageert en het verdraagt — en u kunt op elk moment een bericht sturen.
IN HET DAGELIJKS GEBRUIK
Saxenda in het dagelijks gebruik
Inject once every day
Liraglutide is injected once daily, at any time of day, with or without food. Unlike weekly injections it needs a dose every 24 hours, so it is easiest to pick a convenient time and keep to it.
Start low and build up
Treatment starts at 0.6 mg once daily and rises by 0.6 mg at intervals of at least a week, reaching the 3.0 mg maintenance dose in week 5. The slow climb is there to improve stomach and bowel tolerance.
Tummy, thigh or upper arm
The injection goes under the skin of the abdomen, the thigh or the upper arm. It must never be given into a vein or a muscle. Rotate the site each day to reduce the risk of amyloid deposits building up under the skin.
Check the pen before use
Look at the liquid before you inject. It should be clear and colourless, or almost colourless. With a new pen, do the flow check described in the instructions so you can see a drop appear at the needle tip before setting your dose.
Missed dose: the 12 hour rule
If you remember within 12 hours of your usual time, take the dose as soon as you can. If there is less than 12 hours until the next one, skip it and carry on as normal. Never take an extra dose.
Store pens in the fridge
Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, away from the freezer compartment, and must not be frozen. A pen in use can be stored below 30 degrees Celsius or refrigerated, and is discarded one month after first use.
Drink enough fluid
Nausea, vomiting and diarrhoea are common at the start and can leave you short of fluid. Dehydration has been linked to kidney impairment and acute kidney failure on GLP-1 medicines, so drink plenty and tell your doctor if you cannot keep fluids down.
Keep the diet and activity going
Liraglutide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the daily injection.
Veiligheid voorop
Veiligheid, volledig.
Saxenda is een effectief geneesmiddel — en zoals elk geneesmiddel brengt het risico's met zich mee. Uw arts controleert dit alles vóór het voorschrijven. Dit is het eerlijke beeld, niet alleen geruststelling.
Bijwerkingen, gerangschikt op hoe vaak ze voorkomen
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- Severe and lasting pain in the stomach area that may reach through to your back, which can signal pancreatitis
- Severe pain high in the tummy, usually worst on the right side under the ribs, which can signal gallstones or an inflamed gall bladder
- Breathing problems, or swelling of the face, lips, tongue or throat, which can signal a severe allergic reaction
- Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can lead to kidney failure
- Cold sweat, pale skin, shakiness, headache and confusion, if you also take insulin or a sulfonylurea for diabetes
- A racing or pounding heartbeat while you are resting, which the prescriber needs to review
- Severe stomach pain with bloating and no bowel movement, which can signal a blocked bowel
Very common
very common (≥1/10)
more than 1 in 10 people
- Feeling sick (nausea), most often while the dose is being increased
- Being sick (vomiting)
- Diarrhoea
- Constipation
- Headache
Common
common (≥1/100 to <1/10)
between 1 in 100 and 1 in 10 people
- Low blood sugar symptoms, self-reported and not confirmed by a blood glucose reading, in people without type 2 diabetes
- Trouble sleeping, mainly during the first three months
- Dizziness
- A change in the sense of taste
- Dry mouth
- Indigestion, gastritis or acid reflux
- Pain in the upper part of the tummy
- Wind, burping or a bloated tummy
- Gallstones
- Rash
- Injection site reactions
- Weakness or tiredness
- Raised lipase or amylase on blood tests
Uncommon
uncommon (≥1/1,000 to <1/100)
between 1 in 1,000 and 1 in 100 people
- Dehydration
- A faster heart rate (tachycardia)
- Pancreatitis, which is inflammation of the pancreas
- Delayed stomach emptying
- Inflammation of the gall bladder (cholecystitis)
- Nettle rash (urticaria)
- Generally feeling unwell
Rare
rare (≥1/10,000 to <1/1,000)
between 1 in 10,000 and 1 in 1,000 people
- Anaphylactic reaction, a sudden and severe whole-body allergic reaction
- Acute kidney failure
- Kidney impairment
Frequency not known
frequency not known (cannot be estimated from the available data)
reported, but nobody can yet say how often it happens
- Intestinal obstruction, a blockage of the bowel, reported after the medicine went on the market
- Cutaneous amyloidosis, a lumpy deposit that can build up under the skin at the injection site
Volwassenen met obesitas (BMI ≥30) of overgewicht (BMI ≥27) met ten minste één gewichtsgerelateerde aandoening zoals diabetes type 2, hoge bloeddruk of dyslipidemie.
- Dagelijkse zelfinjectie in dij, buik of bovenarm, op elk moment van de dag maar het liefst steeds op hetzelfde tijdstip.
- De dosis wordt week na week opgebouwd tot de onderhoudsdosis, om maag-darmklachten te beperken.
- Werkt samen met dieet en beweging — het vervangt de leefstijlverandering niet.
WIE HET NIET MAG GEBRUIKEN EN WIE EXTRA VOORZICHTIG MOET ZIJN
- You have ever had an allergic reaction to liraglutide or to any other ingredient in the pen. This is the only absolute contraindication in the EU product information.
- You are pregnant, or you want to become pregnant. Liraglutide should not be used in pregnancy, and treatment is discontinued if pregnancy occurs.
- You are breastfeeding. It is not known whether liraglutide passes into human milk, so it should not be used while breastfeeding.
- You or a close relative have had medullary thyroid carcinoma, or you have multiple endocrine neoplasia syndrome type 2. US labelling makes this an outright contraindication; EU labelling advises caution in anyone with thyroid disease.
- You have had pancreatitis. If pancreatitis is suspected liraglutide is stopped, and if it is confirmed it is not restarted.
- You have gallstones or gall bladder disease. Weight-management trials found more gallstones and gall bladder inflammation on liraglutide than on placebo.
- You have severe kidney impairment, including end-stage kidney disease, or severe liver impairment. Liraglutide is not recommended in these groups.
- You have inflammatory bowel disease or diabetic gastroparesis. Experience is limited and the medicine is not recommended, because it causes stomach and bowel effects.
- You already take another GLP-1 receptor agonist, or you would be using it as a replacement for insulin. Neither is allowed.
- You have New York Heart Association class IV heart failure, or you are 75 years or older. There is no clinical experience in these groups, so use is not recommended.
Wanneer u dringend zorg moet zoeken
Bel bij ernstige, plotselinge of onverwachte symptomen het lokale noodnummer of ga naar de dichtstbijzijnde spoedeisende hulp. Informeer daarna uw arts via de chat van uw account.
Geneesmiddelen en stoffen die een wisselwerking geven
| GENEESMIDDEL OF STOF | WAT ER KAN GEBEUREN | WAT DE ARTS DOET |
|---|---|---|
| Insulin and sulfonylureas (for example gliclazide) | Combined use in type 2 diabetes raises the risk of low blood sugar, sometimes severe. | The prescriber may lower the insulin or sulfonylurea dose and asks for blood glucose self-monitoring. |
| Other GLP-1 receptor agonists | Two medicines acting on the same receptor add side effects without an established extra benefit. | Liraglutide for weight management must not be combined with another GLP-1 receptor agonist. |
| Warfarin and other coumarin blood thinners | No interaction study was done, and a clinically relevant effect on warfarin cannot be excluded. | The prescriber arranges more frequent INR checks when liraglutide is started. |
| Oral medicines in general | Liraglutide slightly delays stomach emptying, which can slow how fast a tablet is absorbed. | Interaction studies showed no clinically relevant delay, so no dose change is required. |
| Paracetamol | Peak paracetamol level fell by 31% and was reached up to 15 minutes later; total exposure was unchanged. | No dose adjustment is needed for paracetamol taken alongside liraglutide. |
| Combined oral contraceptives | Peak ethinylestradiol and levonorgestrel levels fell by 12% and 13%, with no relevant change in total exposure. | The contraceptive effect is expected to be unaffected, so no change is required. |
| Atorvastatin, digoxin and lisinopril | Peak levels fell by 38%, 31% and 27% respectively, with only small changes in total exposure. | No dose adjustment of any of these three is required based on those results. |
| General anaesthesia or deep sedation | Delayed stomach emptying can leave food in the stomach, and pulmonary aspiration has been reported. | Tell the anaesthetic team you take liraglutide before any procedure needing anaesthesia or sedation. |
Laat een arts je situatie beoordelenDit is precies waar de arts op controleert voordat er iets wordt voorgeschreven.
Lees de volledige veiligheidssamenvatting van SaxendaBEWIJS
Wat de klinische onderzoeken lieten zien
The SCALE phase 3 programme tested liraglutide 3.0 mg once daily against placebo in 5,358 adults, and reported a mean body-weight change of -8.0% at 56 weeks compared with -2.6% on placebo.
3,731 adults with BMI >= 30, or >= 27 with dyslipidaemia or hypertension · 56 weeks
SCALE Obesity and Prediabetes. Placebo changed -2.6%. In kilograms the change was -8.4 kg versus -2.8 kg from a mean baseline of 106.3 kg.
Bron: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics3,731 adults without type 2 diabetes · 56 weeks
In the same trial 26.6% of the placebo group reached 5%. For a loss of more than 10% the figures were 32.8% and 10.1%.
Bron: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes at screening · 160 weeks
Placebo changed -1.8%. The weight loss occurred mainly in the first year and was sustained through week 160.
Bron: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics2,254 adults with prediabetes and obesity or overweight · 160 weeks
Estimated time to onset of type 2 diabetes was 2.7 times longer on liraglutide, with a hazard ratio of 0.2 versus placebo.
Bron: Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics422 adults who had already lost at least 5% on a low-calorie diet · 56 weeks
SCALE Maintenance. Placebo changed -0.2%. 81.4% on liraglutide kept at least 5% of the run-in loss, versus 48.9% on placebo.
Bron: SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight lossThese figures are group averages from randomised trials, not a prediction for any one person. Some participants lost far more than the average and some lost very little, and everyone in these trials was also following an energy-restricted diet with exercise counselling alongside the daily injection. The product information also notes that of the people who had lost less than 5% after 12 weeks on the full dose, 93.4% did not go on to reach a 10% loss at one year, which is why the prescriber reviews progress at that point.
ALTERNATIEVEN
Liraglutide vs other EU weight-management medicines
| GENEESMIDDEL | TOEDIENINGSVORM | HOE VAAK | GEBRUIKELIJKE DOSERING | IN DE EU GOEDGEKEURDE INDICATIE | BELANGRIJKSTE BEWIJS |
|---|---|---|---|---|---|
| Semaglutide | Wekelijkse injectie | Eenmaal per week | 0.25–2.4 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | STEP 1: mean -14.9% body weight at 68 weeks versus -2.4% placebo |
| Tirzepatide | Wekelijkse injectie | Eenmaal per week | 2.5–15 mg | Adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with BMI ≥30, or ≥27 to <30 with at least one weight-related comorbidity. | SURMOUNT-1: mean -20.9% body weight at 72 weeks versus -3.1% placebo |
| Orlistat | Orale capsule | Bij elke hoofdmaaltijd | 120 mg per main meal | In conjunction with a mildly hypocaloric diet, for obese patients with BMI ≥30, or overweight patients with BMI ≥28 and associated risk factors. | XENDOS: mean 5.8 kg lost at four years versus 3.0 kg on placebo |
Weet je niet welke bij jou past? De arts bekijkt je voorgeschiedenis en vertelt het je.
Start consult · € 25/maandTOEGANG EN KOSTEN
Saxenda krijgen en wat het kost
Liraglutide is a centrally authorised medicine that is subject to medical prescription across the European Union, so no pharmacy can supply it without a valid prescription from a doctor. Who pays varies a lot by country: most national health systems do not cover it for weight management, so the patient pays the pharmacy directly. The entries for Spain, Germany, the Netherlands, Portugal, Ireland and Poland come from the national sources listed below; the rows for France, Italy, Belgium and Austria record the general position for this indication and are not confirmed against a national decision. The national database linked on each row is the authority on the current position.
Wat je Hi-Doctor betaalt
€ 25/maand (gefactureerd € 25 per 28 dagen)
Beantwoord enkele vragen en een door de EU erkende arts beoordeelt uw casus gemiddeld in minder dan 2 uur. Volledige terugbetaling als het niet bij u past.
Wat de apotheek rekent
Hi-Doctor verkoopt, bewaart en verstrekt geen geneesmiddelen en bepaalt hun prijs niet. Het geneesmiddel betaal je apart bij de apotheek; het bedrag hangt af van het land, de verpakkingsgrootte, of er een generiek middel is en of je zorgverzekering het vergoedt. De officiële databank in de tabel publiceert de actuele toegelaten prijs.
| LAND | AFLEVERSTATUS | VERGOED DOOR DE ZORGVERZEKERING? | OFFICIËLE BRON |
|---|---|---|---|
| Spanje | Alleen op recept | Not reimbursed for weight management | AEMPS CIMA |
Toon de andere landen
| Duitsland | Alleen op recept | Excluded from statutory health insurance as a weight-regulation medicine | PharmNet.Bund AMIce |
|---|---|---|---|
| Frankrijk | Alleen op recept | Not reimbursed for weight management | Base de données publique des médicaments |
| Italië | Alleen op recept | Not reimbursed for weight management | AIFA Medicinali |
| Nederland | Alleen op recept | Restricted, conditions set in Regeling zorgverzekering bijlage 2 | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Alleen op recept | Not reimbursed for weight management | INFARMED Infomed |
| België | Alleen op recept | Not reimbursed for weight management | FAGG-AFMPS medicines database |
| Ierland | Alleen op recept | Reimbursed by the HSE since January 2023, see national criteria | HPRA Find a Medicine |
| Oostenrijk | Alleen op recept | Not reimbursed for weight management | BASG Medikamente Info Austria |
| Polen | Alleen op recept | Not reimbursed, patient pays in full | Rejestr Produktów Leczniczych |
PRIJZEN
Je betaalt alleen als de behandeling wordt goedgekeurd.
€ 25/maand voor gewichtsverlies of € 15/maand (gefactureerd € 45 per 90 dagen) voor haargroei. Voor seksuele gezondheid is een eenmalig consult van € 35 beschikbaar.
Gewichtsverlies
DOORLOPEND PLAN
€ 25/maand
Gefactureerd € 25 per 28 dagen · altijd opzegbaar
Behandelcyclus van 28 dagen
Voor doorlopende behandeling en verlengingen die uw arts beoordeelt.
Verlengingen beoordeeld door uw arts
Start consult
Volledige terugbetaling als een beoordeling niet wordt goedgekeurd
WAT IS INBEGREPEN
- Eerste consult inbegrepen
- Verlengingen beoordeeld door uw arts
- Doorlopende zorg van uw arts
- Altijd opzegbaar
Volledige terugbetaling als een beoordeling niet wordt goedgekeurd
Als een beoordeling niet wordt goedgekeurd, betalen we het bedrag van € 25 voor die periode terug en beëindigen we het plan.
Opmerking: De medicatie, indien de arts deze voorschrijft, wordt apart betaald bij de apotheek tegen de prijs die deze vaststelt. Hi-Doctor verkoopt geen medicijnen.
HOE DE ARTS BESLIST
Een bevoegde arts beoordeelt je situatie, geen algoritme
Een in de EU bevoegde arts leest je vragenlijst en reageert gemiddeld in minder dan 2 uur.
Besluit de arts dat voorschrijven niet veilig is, dan krijg je het consultbedrag volledig terug.
De nazorg loopt via de privéchat in je account, AVG-conform. Geen WhatsApp, geen sms.
VEELGESTELDE VRAGEN
Vragen over Saxenda.
ANDERE GEWICHTSBEHEERSING BEHANDELINGEN
Ontdek gerelateerde behandelingen.
BRONNEN
Waar deze informatie vandaan komt
- 01
Saxenda (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2015
- 02
Saxenda 6 mg/mL solution for injection in pre-filled pen: Annex I Summary of Product Characteristics — European Medicines Agency, 2026
- 03
Saxenda 6 mg/mL solution for injection in pre-filled pen: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 04
Saxenda 6 mg/mL solution for injection in pre-filled pen: Patient Information Leaflet — electronic medicines compendium (emc), 2026
- 05
Liraglutide (Saxenda, Diavic, Zegluxen): NHS medicines A to Z — NHS, 2026
- 06
SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management — New England Journal of Medicine, 2015
- 07
SCALE Maintenance: weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss — International Journal of Obesity, 2013
- 08
Victoza (liraglutide): European public assessment report, medicine overview — European Medicines Agency, 2009
- 09
Saxenda (liraglutide) injection: US prescribing information, boxed warning and contraindications — DailyMed, US National Library of Medicine, 2026
- 10
CIMA: Saxenda presentations, marketing and prescription status in Spain — AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
- 11
Sozialgesetzbuch V § 34: medicines excluded from statutory health insurance, including those for weight regulation — Bundesministerium der Justiz (gesetze-im-internet.de), 2026
- 12
Liraglutide: preparaattekst and vergoeding conditions in the Netherlands — Farmacotherapeutisch Kompas, Zorginstituut Nederland, 2026
- 13
Liraglutide (Saxenda): health technology assessment and HSE reimbursement decision — National Centre for Pharmacoeconomics (Ireland), 2023
- 14
Rejestr Produktow Leczniczych: Saxenda registration record in Poland — Centrum e-Zdrowia (Poland), 2026
- 15
INFOMED: base de dados de medicamentos de uso humano — INFARMED (Portugal), 2026
- 16
STEP 1: Once-weekly semaglutide in adults with overweight or obesity — New England Journal of Medicine, 2021
- 17
SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity — New England Journal of Medicine, 2022
- 18
XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study — Diabetes Care, 2004
- 19
Wegovy (semaglutide) solution for injection: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 20
Xenical 120 mg hard capsules: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
Beoordeeld door het medische team van Hi-Doctor · Laatst beoordeeld op 2026-07-27 · Volgende beoordeling op 2027-07-27
Deze pagina bevat voorlichting over een geneesmiddel. Het is geen advies om het te gebruiken en geen vervanging van een medisch consult. Alleen een bevoegde arts die je voorgeschiedenis heeft bekeken, kan beoordelen of een behandeling geschikt voor je is.
Ontdek of het bij u past
Kijk of Saxenda geschikt is voor u.
Beantwoord enkele vragen en een door de EU erkende arts beoordeelt uw casus gemiddeld in minder dan 2 uur. Volledige terugbetaling als het niet bij u past.